12:00 AM
 | 
Mar 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Quad elvitegravir/cobicistat/emtricitabine/tenofovir: Additional Phase III data

Additional data from the 96-week, double-blind, international Phase III Study 103 trial in 708 treatment-naive patients showed that once-daily Quad led to significantly smaller increases from baseline in triglycerides vs. ritonavir-boosted atazanavir plus Truvada emtricitabine/tenofovir (8 vs. 23 mg/dL, p=0.006). Mean increases in CD4+ cell counts were similar between treatment groups (207 vs. 211 cell/mm 3). Data were presented at the Retroviruses and Opportunistic Infections meeting in Seattle. Last year, Gilead reported that Quad...

Read the full 349 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >